NHS England Regional Medicines Optimisation Committee has published a briefing paper on adalimumab. The briefing provides a summary of advice on the next steps for commissioners and providers; practical advice in the context of homecare services; and progress to date in planning for the patent expiry of the originator adalimumab product Humira in October 2018.
In addition, a clinical briefing sheet is provided.
Full details can be found on the Specialist Pharmacy Service (SPS) webpage